Drug Database
Back to search

Poland· PL-100304346

Relvar Ellipta

A vilanterol und fluticason furoat product containing fluticasoni furoas + vilanterolum, registered in Poland by GlaxoSmithKline (Ireland) Limited. The same ATC class is registered in 11 of our 19 countries.

ATC R03AK10

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedRelvar ElliptaATCR03AK10REGISTER NO.PL-100304346PACKS LISTED3CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about fluticasoni furoas + vilanterolumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Vilanterol und fluticason furoat is registered in 11 of 19 countries.

Countries holding a registration under ATC R03AK10 (vilanterol und fluticason furoat), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 7 of them publish a price we can compare per daily dose
Search vilanterol und fluticason furoat products by name

Vilanterol und fluticason furoat · ATC R03AK10

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of vilanterol und fluticason furoat costs, country by country.

Normalised to the WHO defined daily dose (25 mcg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Vilanterol und fluticason furoat · price per daily dose (25 mcg)

USD · FX 28 Sept 2026

  • CH Switzerland$0.30
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Fluticasoni furoas + Vilanterolum
Manufacturer
GlaxoSmithKline (Ireland) Limited
Country
Poland (PL)
ATC code
R03AK10
ATC class
Vilanterol und Fluticason furoat
Defined daily dose
25 mcg, Inhal
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 3

  • gtin
    05909991088026
  • gtin
    05909991088033
  • gtin
    05909991088040

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

1 interaction on record for vilanterol und fluticason furoat.

Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check vilanterol und fluticason furoat against other medicinesHow interaction checks work

Vilanterol und fluticason furoat · interactions on record

1 record

1 more interaction with mechanism and management, from a commercially licensed source.

Sign in to check
Mechanism and what to do, in the interaction check
Interaction register. Grades as the source publishes them.

Same medicine, other countries

Vilanterol und fluticason furoat in 8 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All vilanterol und fluticason furoat products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Relvar Ellipta, Revinty Ellipta
  • Liechtenstein · Relvar Ellipta, Revinty Ellipta
  • Norway · Relvar Ellipta, Revinty Ellipta

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/d7b02d65-7734-4b88-8609-3a7e030d951f
GET /v1/drugs/d7b02d65-7734-4b88-8609-3a7e030d951f?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Proszek do inhalacji, podzielony",
  "source": "urpl",
  "strength": "184 mcg + 22 mcg",
  "packaging": "05909991088026 ¦ Rp ¦ EU/1/13/886/004 ¦ 86795\n1 inhalator 14 dawek\n05909991088033 ¦ Rp ¦ EU/1/13/886/005 ¦ 86796\n1 inhalator 30 dawek\n05909991088040 ¦ Rp ¦ EU/1/13/886/006 ¦ 86797\n3 inhalatory 30 dawek",
  "substance": "Fluticasoni furoas 184 mcg + Vilanterolum 22 mcg",
  "common_name": "Fluticasoni furoas + Vilanterolum",
  "pl_product_id": "100304346",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about vilanterol und fluticason furoat.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console